Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics is attractive because two first-in-class approvals have validated its peptide discovery platform, with Icotyde already showing strong early PsO uptake and rusfertide approved for erythrocytosis in PV, while both are commercialized by stronger partners that can scale them efficiently. The company’s economics are compelling: it ended 2Q26 with $849.5M in cash and investments, received $275M in rusfertide-related payments, has up to about $1.4B in milestones, and collects tiered royalties of 6-10% on Icotyde and 14-29% on Mimrylo. Beyond the partnered revenue base, wholly owned programs like PN-881 and PN-477 add upside in large addressable markets, and the $300M buyback underscores balance sheet strength and shareholder returns.

Protagonist Therapeutics is viewed negatively because its valuation depends heavily on a small number of partnered, commercial-stage programs, making execution by Johnson & Johnson and Takeda a central vulnerability while still leaving the company exposed to clinical, regulatory, and funding setbacks. Competition is also a major drag: icotrokinra faces entrenched products such as Otezla and Besremi, while future entrants in IL-23 and IL-17 could limit penetration and pricing power, especially if payer access or formulary status proves unfavorable. Although management-linked collaboration revenue can swing results, the core pipeline still carries meaningful development risk, and higher-than-expected spending on wholly owned programs could pressure financial flexibility before those assets can offset the competitive burden.